Important Update on Daybue Reimbursement in Canada:
The Canadian Rett community should be aware that the Canadian Drug Agency (CDA) has issued a draft recommendation not to approve Daybue for public reimbursement in Canada. ORSA Canada submitted a strong letter of support during the first round of consultations, advocating for access to this important treatment. We remain deeply committed to Canadian families and will be submitting another letter of feedback in response to the draft recommendation, urging the CDA to reconsider their decision.
Kens
Important Update on Daybue Reimbursement in Canada: The Canadian...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.81 |
Change
-0.155(1.20%) |
Mkt cap ! $1.609B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.70 | $2.892M | 224.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 260 | $12.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.81 | 191 | 2 |
View Market Depth
| Last trade - 14.17pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |